Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) announced its earnings results on Monday. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13), FiscalAI reports. The business had revenue of $5.65 million for the quarter, compared to analyst estimates of $29.00 million.
Prelude Therapeutics Stock Performance
Shares of NASDAQ PRLD opened at $3.45 on Monday. The firm’s 50 day moving average price is $4.00 and its 200-day moving average price is $4.07. Prelude Therapeutics has a 52-week low of $1.29 and a 52-week high of $6.83. The company has a market cap of $275.32 million, a PE ratio of -4.73 and a beta of 1.22.
Analyst Upgrades and Downgrades
PRLD has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Tuesday, October 27th. Wall Street Zen downgraded Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. JPMorgan Chase & Co. began coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They set an “overweight” rating and a $12.00 price objective for the company. Citigroup reiterated a “market outperform” rating on shares of Prelude Therapeutics in a research note on Wednesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Prelude Therapeutics in a research note on Wednesday, July 29th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.75.
Get Our Latest Research Report on PRLD
Prelude Therapeutics Company Profile
Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.
Read More
- Five stocks we like better than Prelude Therapeutics
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
